Among 3596 HIV-positive participants enrolled in the Botswana Combination Prevention Project who self-reported no prior antiretroviral (ARV) therapy use and were tested for viral load (n
951; 27% of all participants), 136 (14%) had HIV-1 RNA less than 400 copies/ml. ARV drugs were detected in 52 (39%) of 134 participants tested. Adjusting for undisclosed ARV use increased the overall estimate of virally suppressed individuals on ARV therapy by 1.4% from 70.2 to 71.6%.
aBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana
bHarvard T.H. Chan School of Public Health
cMassachusetts General Hospital
dBrigham and Women's Hospital, Boston, Massachusetts, USA
fBotswana Ministry of Health and Wellness, Gaborone, Botswana
gJohns Hopkins Hospital, Baltimore, Maryland, USA.
Correspondence to Sikhulile Moyo, MSc, MPH, PhD, Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana. Tel: +267 3902671; fax: +267 3901284; e-mail: firstname.lastname@example.org,email@example.com
Received 3 February, 2018
Revised 19 April, 2018
Accepted 27 April, 2018